Takeda Pharmaceutical Company Limited (TAK) SC 13G Xilio Therapeutics / TAKEDA PHARMACEUTICAL ownership change

Exhibit 99.2

JOINT FILING AGREEMENT

The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Common Stock of Xilio Therapeutics, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the undersigned. In addition, each party to this Agreement expressly authorizes each other party to this Agreement to file on its behalf any and all amendments to such Statement on Schedule 13G.

This Agreement may be executed in counterparts and each of such counterparts taken together shall constitute one and the same instrument.

Date: January 14, 2022

TAKEDA PHARMACEUTICAL COMPANY LIMITED
By	/s/ Yoshihiro Nakagawa
	Name:	Yoshihiro Nakagawa
	Title:	Corporate Officer, Global General Counsel

TAKEDA VENTURES, INC.
By	/s/ Michael Martin
	Name:	Michael Martin
	Title:	President